AngioDynamics Q3 pro forma sales up 8%; GAAP loss $4.73/sh on $159.5M goodwill impairment; guidance cut

ANGIODYNAMICS INC

2024-Q3 EPS reported -$4.26 revenue$232,934,000

Reported net sales $75.2M; pro forma $66.0M (+8.0% YoY). GAAP net loss $190.4M ($4.73/sh) includes $159.5M goodwill impairment and $22.0M litigation settlement.
Pro forma gross margin 51.1% (-290bps); adj. loss per share $(0.16); adj. EBITDA -$3.6M.
Med Tech sales $25.7M (+12.6%); NanoKnife +46.7%, Auryon +14.7%. Med Device sales $40.3M (+5.2%).
Subsequent events: settled BD/Bard patent litigation; received FDA 510(k) clearance for AlphaVac in pulmonary embolism.
FY2024 guidance lowered: net sales $270-275M (prior $320-325M) due to divestiture/discontinuations; adj. loss per share $(0.54)-(0.58).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ANGIODYNAMICS INC reported financial results for the fiscal third quarter ended February 29, 2024.

Period: the fiscal third quarter ended February 29, 2024
Result: reported results

Exact text from the filing

On April 4, 2024, AngioDynamics issued a press release announcing financial results for the fiscal third quarter ended February 29, 2024.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

ANGIODYNAMICS INC filing history →

Source: SEC EDGAR

accession 0001140361-24-017807

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.